Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis
In brief
FcRn inhibitors lower MG muscle scores by about 3.6 points versus placebo
In a network meta-analysis of 27 trials, FcRn inhibitors improved quantitative MG scores by roughly 3.6 points and MG-ADL scores by 2 points compared with placebo, matching the benefit of complement inhibitors and B-cell depletion. However, FcRn drugs doubled the odds of treatment-related adverse events, so safety must be weighed while awaiting direct comparative trials.
- Journal
- Neurology (Q1)
- Published
- 17 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Nilay P McLaren, Matteo Rosati, Wayne Zhong, Sheena Hussain, Melissa C Funaro, Richard J Nowak, et al.
- PMID
- 42467874
- DOI
- 10.1212/WNL.0000000000218351
Why clinicians should know about it
- Picked for Family Practice (top studies of the week, 19 July 2026).
- Picked for Pediatrics and Child Health (top studies of the week, 19 July 2026): Recent Pediatrics, Perinatology and Child Health research from a high-quartile journal.
- Picked for Transplantation (top studies of the week, 19 July 2026): High-quality evidence in a top journal
- Picked for Neurology (clinical) (top studies of the week, 19 July 2026).
Abstract
BACKGROUND AND OBJECTIVES: In the past decade, several novel therapies have shown promise in treating generalized myasthenia gravis (MG); however, no head-to-head prospective studies have compared their efficacy and safety. To assist clinicians in navigating this complex treatment landscape, we sought to compare treatments while accounting for differences in trial populations. METHODS: We conducted a Bayesian network meta-analysis (PROSPERO ID: CRD42023428733) of MG treatments. We searched Scopus, Embase, Web of Science, CENTRAL, and MEDLINE up to May 2, 2025, for randomized trials in MG. Two independent reviewers (N.M. and M.R.) identified prospective multiarm studies of adults (18 or older) with generalized MG that reported mean treatment difference, with uncertainty, in MG-Activities of Daily Living (MG-ADL) or Quantitative MG (QMG) score change from baseline. RESULTS: Of 4,823 eligible studies, 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) were included that targeted B cells, neonatal Fc receptor (FcRn), complement activity, CD40, and interleukin-6 signaling, as well as immunoglobulin G and broad immunosuppression therapy. Compared to those treated with placebo and standard of care, QMG scores decreased by an average of -3.63 (95% credible interval -4.43 to -2.77) points more in patients treated with FcRn inhibitors, -2.59 (-3.92 to -1.28) points more in patients treated with C5 complement inhibitors (C5i), and -2.50 (-5.11 to 0.12) points more in patients treated with CD19+ B-cell depletion therapy (BCDT). The MG-ADL treatment effects were -1.93 (-2.21 to -1.65) for FcRn inhibitors, -1.84 (-2.48 to -1.19) for C5i, and -1.91 (-2.97 to -0.84) for CD19+ BCDT. Sensitivity analyses detected potential confounding of treatment effects by age and sex. Patients treated with FcRn inhibitors had greater odds of treatment-related adverse events (odds ratio 2.20 [1.52-3.38]) compared with the placebo group, while C5i and CD19+ BCDT showed odds comparable to placebo. DISCUSSION: FcRn inhibitors, C5i, and CD19+ BCDT showed comparable efficacy in terms of QMG and MG-ADL reduction because meaningful differences were not observed between treatment classes. Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes. Prospective comparative efficacy studies are warranted.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.